The MonarchE trial: improving the clinical outcome in HR+/HER2- early breast cancer: recent results and next steps

被引：4
|
作者：
Bertucci, Francois [1 ,2 ,3 ]
Finetti, Pascal [1 ]
Mamessier, Emilie [1 ]
De Nonneville, Alexandre [1 ,2 ]
机构：
[1] Aix Marseille Univ, Paoli Calmettes Inst, Canc Res Ctr Marseille, Lab Predict Oncol,INSERM,CNRS,UMR 1068,UMR 725,Tea, Marseille, France
[2] Paoli Calmettes Inst, Dept Med Oncol, Marseille, France
[3] Paoli Calmettes Inst, Dept Med Oncol, 232 Bd St Marguer, F-13009 Marseille, France
来源：
CANCER COMMUNICATIONS | 2023年 / 43卷 / 08期
关键词：
PALBOCICLIB;
D O I：
10.1002/cac2.12466
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：938 / 942
页数：5
相关论文
共 50 条
  • [21] Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
    Hui, Rina
    Pearson, Alex
    Cortes, Javier
    Campbell, Christine
    Poirot, Camille
    Azim, Hatem A., Jr.
    Fumagalli, Debora
    Lambertini, Matteo
    Daly, Fergus
    Arahmani, Amal
    Perez-Garcia, Jose
    Aftimos, Philippe
    Bedard, Philippe L.
    Xuereb, Laura
    Scheepers, Elsemieke D.
    Vicente, Malou
    Goulioti, Theodora
    Loibl, Sibylle
    Loi, Sherene
    Pierrat, Marie-Jeanne
    Turner, Nicholas C.
    Andre, Fabrice
    Curigliano, Giuseppe
    CLINICAL CANCER RESEARCH, 2020, 26 (02) : 354 - 363
  • [22] Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
    Geneviève Gauthier
    Patrick Gagnon-Sanschagrin
    Annie Guérin
    Rebecca Burne
    Tania Small
    Polly Niravath
    Anand A. Dalal
    Advances in Therapy, 2018, 35 : 503 - 514
  • [23] Efficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C. -S.
    Wei, R.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    SWISS MEDICAL WEEKLY, 2022, 152 : 48S - 48S
  • [24] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Piudo, Natalia Chavarria
    Blancas, Isabel
    Flores, Encarna Gonzalez
    Carrasco, Fernando Henao
    Alvarez, Pilar Lopez
    Pancorbo, David Morales
    Casado, Salvador Gamez
    Garrido, Maria de la Cabeza Lomas
    Garcia, Jose Manuel Rodriguez
    Guisado, Antonia Martinez
    Vega, Adrian Sanchez
    Borrego, Manuel Ruiz
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12): : 3131 - 3141
  • [25] Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer
    Loi, Sherene
    Johnston, Stephen
    Arteaga, Carlos
    Graff, Stephanie
    Chandarlapaty, Sarat
    Goetz, Matthew
    Desmedt, Christine
    Reis-Filho, Jorge
    Sasano, Hironobu
    Rodrik-Outmezguine, Vanessa
    Sireci, Anthony
    Rubenstein, Cynthia Sandoval
    Won, Helen
    Liu, Deli
    Litchfield, Lacey M.
    Turner, Nicholas
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-high-risk early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Huober, J.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C.
    Wei, R. J.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S151 - S151
  • [27] A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2- advanced breast cancer
    Jerusalem, Guy
    Bachelot, Thomas
    Barrios, Carlos
    Neven, Patrick
    Di Leo, Angelo
    Janni, Wolfgang
    de Boer, Richard
    CANCER TREATMENT REVIEWS, 2015, 41 (02) : 94 - 104
  • [28] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Chavarria Piudo, Natalia
    Blancas, Isabel
    Gonzalez Flores, Encarnacion
    Henao Carrasco, Fernando
    Lopez Alvarez, Pilar
    Morales Pancorbo, David
    Baena-Canada, Jose Manuel
    Lomas Garrido, Maria de la Cabeza
    Rodriguez, Jose Manuel
    Martinez Guisado, Antonia
    Sanchez Vega, Adrian
    Ruiz-Borrego, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Clinicopathological and molecular features of HR+/HER2- breast cancer patients with distinct endocrine resistance patterns
    Zhang, Siwei
    Wang, Han
    Zhang, Hang
    Zhuang, Qingyuan
    Zhu, Xiaohui
    Xiao, Yi
    Jiang, Yizhou
    CHINESE JOURNAL OF CANCER RESEARCH, 2025, 37 (01)
  • [30] Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
    Christiansen, Emilie Adrian
    Kuemler, Iben
    FUTURE SCIENCE OA, 2024, 10 (01):
12345